It may cost a lot of labour forces and financial forces to launch a new Phase 3 randomized clinical trial, thus this study aims to test the efficacy of the combination of anti-PD1 and HDAC inhibitors in NKTCL immunocompetent preclinical modes, factor analysis of the contribution of each agent, and explore potential response biomarkers. The gene discussed is HDAC9; the disease is extranodal nasal NK/T cell lymphoma.